Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Gastric Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
6 drugs · 167 active trials
4 drugs · 97 active trials
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Carboplatin | Phase 2 | Phase 2 | 9 | 4 | 0 | 22 | 0 | — | — | 1997-05 |
| Durvalumab | Phase 2 | Phase 2 | 7 | 3 | 0 | 12 | 0 | — | — | 2015-02 |
| Gemcitabine | Phase 2 | Phase 2 | 6 | 3 | 0 | 13 | 0 | — | — | 1997-12 |
| Adebrelimab | Phase 2 | Phase 2 | 5 | 3 | 0 | 5 | 0 | — | — | Aug 3, 2024 |
| Cyclophosphamide | Phase 2 | Phase 2 | 4 | 3 | 0 | 18 | 0 | — | — | 2007-08 |
| Fludarabine | Phase 2 | Phase 2 | 4 | 3 | 0 | 14 | 0 | — | — | 2007-08 |
| Aldesleukin | Phase 2 | Phase 2 | 4 | 3 | 0 | 10 | 0 | — | — | 1998-01 |
| Doxorubicin | Phase 2 | Phase 2 | 4 | 2 | 0 | 9 | 0 | — | — | 1997-12 |
| Hyperthermic Intraperitoneal Chemotherapy | Phase 2 | Phase 2 | 4 | 2 | 0 | 8 | 0 | — | — | Feb 2, 2016 |
| Lenvatinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 7 | 0 | — | — | Oct 24, 2017 |
| Tremelimumab | Phase 2 | Phase 2 | 3 | 2 | 0 | 5 | 0 | — | — | Oct 22, 2018 |
| Zanidatamab | Phase 2 | Phase 2 | 3 | 2 | 0 | 4 | 0 | — | — | Mar 23, 2020 |
| Mitomycin | Phase 2 | Phase 2 | 2 | 2 | 0 | 6 | 0 | — | — | 2001-09 |
| Cabozantinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Sep 5, 2017 |
| Futibatinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Jul 21, 2014 |
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Dec 3, 2019 |
| Adavosertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Datopotamab Deruxtecan | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Nov 12, 2020 |
| Immunotherapy | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Jul 16, 2025 |
| Osimertinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Pemetrexed | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | 2004-05 |
| Sunitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2006-12 |
| Savolitinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2014-09 |
| Dexamethasone | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Dec 3, 2018 |
| Pemigatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Feb 27, 2015 |
| Regorafenib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2013-07 |
| Rucaparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2015-02 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Anti-PD1 Monoclonal Antibody | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Jan 1, 2023 |
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jan 7, 2015 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Dostarlimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Apr 7, 2021 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2011-11 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 14, 2013 |
| Metformin | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Jul 1, 2020 |
| Rituximab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2010-04 |
| Talazoparib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2016-06 |
| Trastuzumab Deruxtecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 12, 2020 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2009-09 |
| Berzosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 16, 2020 |
| Binimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Camizestrant | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Immunomodulatory Oligonucleotide | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 19, 2023 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Neratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jan 12, 2024 |
| Palbociclib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.